PCSA CLUSTER SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

PCSA ▲ +4.95% at T+20d

LONG call ✓ call won +4.95% · α vs SPY -4.47% · entry $2.53 → $2.65

Next anchor: T+60d in 12d

Currently $2.17 · -14.06% from $2.53 entry

Entry anchored
Mar 30, 03:55 PM ET
via Databento tick

T+1d

+3.09%

call +3.09% · α +2.34%

$2.60

settled 2mo ago

T+5d

+19.60%

call +19.60% · α +15.66%

$3.02

settled 2mo ago

T+20d

+4.95%

call +4.95% · α -4.47%

$2.65

settled 7w ago

T+60d

—

call — · α —

—

in 12d

Price Chart

Loading chart...

Executive Summary

Nine insiders at Processa Pharmaceuticals, including the CEO, CFO, and multiple directors, made open-market purchases totaling $43K at $2.54/share over a 7-day window. This represents approximately 0.6% of the company's $7M market cap — a significant cluster by proportionality. The buying is unanimous and concentrated among top leadership, signaling strong conviction ahead of a potential catalyst.

Key Financial Metrics

Direction

buying

Total Value

$43.0K

Insiders

9

Actionable Insight

Unanimous insider buying at a micro-cap biotech with 86% analyst bullishness suggests management sees material upside. Monitor for near-term catalysts (trial data, partnership, financing). The cluster's size relative to market cap is unusually large for a single week — treat as a strong vote of confidence.

Key Facts

9 insiders bought $43K in open-market purchases at $2.54/share
CEO George Ng bought $5K, CFO Russell Skibsted bought $6K
Total cluster value is ~0.6% of $7M market cap
All 9 trades were open-market buys (code P) — no sales or non-cash transactions
Prior 30-day insider activity: 7 buys totaling $36K, now accelerating

Financial Impact

$43K in insider purchases, ~0.6% of market cap

insider ownershipmarket sentiment

Risk Factors

Micro-cap biotech with $7M market cap is inherently high-risk and illiquid
Insider buying does not guarantee positive catalysts — clinical failures can destroy value
Historical calibration shows score-6 reports on this segment have only 25% win rate at T+20

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

86% bullish (7 analysts)

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

Document	Accession Number
CLUSTER Data (Synthetic)	cluster-PCSA-1777581232417

7 reports for PCSA

T+1T+5T+20T+60

83% Hit rate 5 of 6 directional calls best @ T+5▲ +19.60%Mar 31, 2026

Filters

Reports for PCSA — sortable, filterable
	Type				Now
Jun 1, 2026 11d ago	Insider Cluster BULLISH ★ 4/10	$2.92 $2.80	▼ −4.11%	▼ −3.39%	$2.17 (−25.68%)
May 19, 2026 24d ago	Insider Cluster BULLISH ★ 5/10	$2.61 $2.57	▼ −1.72%	▼ −1.92%	$2.17 (−16.86%)
May 19, 2026 24d ago	Insider Cluster BULLISH ★ 5/10	$2.61 $2.57	▼ −1.72%	▼ −1.92%	$2.17 (−16.86%)
Apr 30, 2026 6w ago	Insider Cluster BULLISH ★ 4/10	$2.70 $2.55	▼ −5.56%	▼ −5.78%	$2.17 (−19.63%)
Apr 15, 2026 8w ago	Insider Cluster BULLISH ★ 5/10	$2.96 $3.18	▲ +7.43%	▲ +7.18%	$2.17 (−26.69%)
Mar 31, 2026 10w ago	Insider Cluster BULLISH ★ 6/10	$2.53 $2.60	▲ +3.09%	▲ +2.34%	$2.17 (−14.06%)
Mar 31, 2026 10w ago	Insider Cluster BULLISH ★ 6/10	$2.53 $2.60	▲ +3.09%	▲ +2.34%	$2.17 (−14.06%)

US Market Status

Market Closed — Opens Mon (48h 55m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access